Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Longxin Fund has a significant holding in Tiger Med, with its Longxin Xianrui Mixed A Fund (519937) holding 50,000 shares, representing 0.71% of the fund's net value, making it the seventh-largest holding [2][5]. - The fund has realized a floating profit of approximately 127,000 CNY today, with a total floating profit of 162,000 CNY during the three-day increase [2][5]. - The Longxin Xianrui Mixed A Fund was established on June 2, 2016, with a current size of 16.30 million CNY. Year-to-date returns are 1.52%, with a one-year return of 5.08% and a cumulative return of 43.7% since inception [2][5]. Fund Manager Performance - The fund manager, Ye Song, has a tenure of 15 years and 3 days, managing assets totaling 1.397 billion CNY, with the best fund return during his tenure being 98.51% and the worst being -16.83% [3][6]. - Co-manager Cheng Fang has a tenure of 5 years and 88 days, managing assets of 538 million CNY, with the best return of 16.42% and the worst return of 1.3% during his tenure [3][6].